Welcome to our dedicated page for Integra Lifesciences Hldgs Cp SEC filings (Ticker: IART), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integra LifeSciences Holdings Corporation filings document regulatory disclosures for a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Forms 8-K cover operating results and financial condition, including GAAP-to-non-GAAP reconciliations for organic revenue, adjusted EBITDA, adjusted earnings per share, net debt and free cash flow, as well as guidance-related disclosures.
Proxy and material-event filings address board elections, shareholder voting, executive compensation and equity incentive plan amendments. Other filings describe leadership appointments, employment and severance arrangements, and financing matters such as the company’s accounts receivable securitization facility used for liquidity and ongoing business funding.
Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences Holdings Corp (IART), reported two sales of company common stock on 09/01/2025. The filing shows a disposition of 2,139 shares at $15.13, leaving 29,059 shares beneficially owned after that transaction, and a separate disposition of 1,412 shares at $15.13, leaving 27,647 shares beneficially owned after that transaction.
The Form 4 is signed by an attorney-in-fact and includes a Power of Attorney exhibit; it documents insider selling and fulfills disclosure requirements under Section 16.
Integra LifeSciences (IART) Form 4: Director Stuart Essig reported multiple internal transfers of common stock in August 2025. On August 14, 2025 he transferred 200,000 shares to a grantor trust for which his spouse is trustee and received assets of equal fair market value. The same date shows a 200,000-share acquisition entry at $13.62 and a 200,000-share disposition at $13.62 reflecting the trust transfer. Prior to that, on August 8, 2025, 180,080 shares were distributed to Essig from GRAT E as an annuity payment and 500,000 shares were distributed from GRAT F as an annuity payment; GRAT F was then terminated because remaining shares were insufficient to satisfy the annuity obligation. Following the reported transactions, the filings list 1,152,236 shares beneficially owned directly and various indirect holdings through trusts (including 219,920 by GRAT E and 213,115 by a family trust).